Biodexa Pharmaceuticals (BDRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biodexa Pharmaceuticals has successfully appealed a Nasdaq delisting decision, securing an extension to meet the $1.00 minimum bid price requirement. This development provides the company with additional time to stabilize its stock price, crucial for its continued Nasdaq listing. Investors will be watching closely as Biodexa works towards compliance by the end of October 2024.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.